

[President Biden's Executive Order on Competition: Three Important Takeaways for Tech and Life Sciences Companies](#) ›

Key takeaways

The executive order targets practices and mergers in the tech and life sciences industries – conduct that may have flown under the radar before may now trigger regulatory attention

Tech and life sciences companies should expect heightened merger scrutiny, increased focus on collection and use of sensitive personal information, and laser focus on drug prices and conduct that may potentially delay the entry of generics and biosimilars

On July 9, President Joe Biden issued an executive order on “Promoting Competition in the American Economy.” With 72 initiatives and directives by more than a dozen federal agencies, the order seeks to aggressively “reduce the trend of corporate consolidation, increase competition, and deliver concrete benefits to America’s consumers, workers, farmers, and small businesses.”

[Read full article](#) ›

Recent headlines

[President Biden Takes Aim at Enforceability of Noncompete Agreements via Federal Agency Call to Arms](#) ›

[FCC Relaxes Rules on Marketing and Importing Devices](#) ›

[Colorado Becomes Third State to Pass a Comprehensive Privacy Law](#) ›

[View all](#) ›



This publication is an attorney advertisement which provides a general description of the law; it is not intended to provide specific legal advice or to establish an attorney-client relationship.

Copyright © 2021 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS, UK. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley as the author. All other rights reserved.